Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?
作者信息
Pfeiffer Ruth M, Rotman Yaron, O'Brien Thomas R
机构信息
Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
出版信息
Hepatology. 2020 Sep;72(3):794-796. doi: 10.1002/hep.31413.
Abstract
摘要
相似文献
1
Genetic Determinants of Cirrhosis and Hepatocellular Carcinoma Due to Fatty Liver Disease: What's the Score?非酒精性脂肪性肝病所致肝硬化和肝细胞癌的遗传决定因素：情况如何？
Hepatology. 2020 Sep;72(3):794-796. doi: 10.1002/hep.31413.
2
KLF6 in nonalcoholic fatty liver disease: role of fibrogenesis and carcinogenesis.KLF6在非酒精性脂肪性肝病中的作用：纤维化形成与致癌作用
Gastroenterology. 2008 Jul;135(1):309-12. doi: 10.1053/j.gastro.2008.06.014. Epub 2008 Jun 17.
3
PNPLA3 rs738409C/G polymorphism in cirrhosis: relationship with the aetiology of liver disease and hepatocellular carcinoma occurrence.载脂蛋白基因 PNPLA3 rs738409C/G 多态性与肝硬化：与肝病病因及肝细胞癌发生的关系。
Liver Int. 2011 Sep;31(8):1137-43. doi: 10.1111/j.1478-3231.2011.02534.x. Epub 2011 Apr 19.
4
Human livers with cirrhosis and hepatocellular carcinoma have less mitochondrial DNA deletion than normal human livers.患有肝硬化和肝细胞癌的人类肝脏中的线粒体DNA缺失比正常人类肝脏少。
Life Sci. 1999;64(19):1785-91. doi: 10.1016/s0024-3205(99)00117-4.
5
Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen?铁、遗传性血色素沉着症基因（HFE）突变与肝细胞癌：肝脏铁是一种致癌物吗？
Clin Gastroenterol Hepatol. 2003 Jul;1(4):246-8.
6
Association of PNPLA3 (rs738409) & TM6SF2 (rs58542926) and ATG16L1 (rs2241880) genetic variants with susceptibility to hepatocellular carcinoma in a group of Egyptian patients with HCV-induced liver cirrhosis.PNPLA3（rs738409）、TM6SF2（rs58542926）及自噬相关基因16样蛋白1（ATG16L1，rs2241880）基因变异与一组埃及丙型肝炎病毒诱导的肝硬化患者肝细胞癌易感性的关联
Tumour Virus Res. 2023 Jun;15:200256. doi: 10.1016/j.tvr.2023.200256. Epub 2023 Feb 16.
7
Serum Gc system in liver cirrhosis and hepatoma.
Hum Genet. 1977 Nov 10;39(2):225-8. doi: 10.1007/BF00287016.
8
HFE gene mutations in alcoholic and virus-related cirrhotic patients with hepatocellular carcinoma.酒精性和病毒相关性肝硬化合并肝细胞癌患者的HFE基因突变
Am J Gastroenterol. 2002 Apr;97(4):1016-21. doi: 10.1111/j.1572-0241.2002.05553.x.
9
Histological and genetic heterogeneity in synchronous hepatocellular carcinoma.同步性肝细胞癌中的组织学和基因异质性
Gut. 2001 Jul;49(1):155-6. doi: 10.1136/gut.49.1.155a.
10
Warning: Genome-wide association studies can be misleading. An example in hepatology.警告：全基因组关联研究可能会产生误导。肝脏病学中的一个例子。
Hepatology. 2011 Apr;53(4):1408; author reply 1408-9. doi: 10.1002/hep.24198.
引用本文的文献
1
Genetics of Metabolic Dysfunction-associated Steatotic Liver Disease: The State of the Art Update.代谢功能障碍相关脂肪性肝病的遗传学：最新进展。
Clin Gastroenterol Hepatol. 2024 Nov;22(11):2177-2187.e3. doi: 10.1016/j.cgh.2024.05.052. Epub 2024 Jul 31.
2
Editorial: Insights in gastroenterology: 2021.社论：2021年胃肠病学洞察
Front Med (Lausanne). 2022 Sep 8;9:1008157. doi: 10.3389/fmed.2022.1008157. eCollection 2022.
3
and tea regulate AMPK signaling pathway to retard the progress of nonalcoholic fatty liver disease.茶调节AMPK信号通路以延缓非酒精性脂肪性肝病的进展。
Food Nutr Res. 2022 Jun 10;66. doi: 10.29219/fnr.v66.7652. eCollection 2022.
4
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial.PNPLA3、TM6SF2和MBOAT7对非酒精性脂肪性肝病营养治疗反应的影响：一项随机对照试验。
Front Med (Lausanne). 2021 Oct 8;8:734847. doi: 10.3389/fmed.2021.734847. eCollection 2021.
5
Genetic Contribution to Non-alcoholic Fatty Liver Disease and Prognostic Implications.遗传因素对非酒精性脂肪性肝病的影响及其预后意义。
Curr Diab Rep. 2021 Feb 5;21(3):8. doi: 10.1007/s11892-021-01377-5.
本文引用的文献
1
Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.载脂蛋白基因 PNPLA3、TM6SF2 和 HSD17B13 变异与普通人群肝硬化和肝细胞癌风险的联合作用。
Hepatology. 2020 Sep;72(3):845-856. doi: 10.1002/hep.31238.
2
Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases.酒精性肝病的诊断与治疗：美国肝病研究协会2019年实践指南
Hepatology. 2020 Jan;71(1):306-333. doi: 10.1002/hep.30866.
3
Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者的肝细胞癌风险。
Gastroenterology. 2018 Dec;155(6):1828-1837.e2. doi: 10.1053/j.gastro.2018.08.024. Epub 2018 Aug 23.
4
Breast Cancer Risk Model Requirements for Counseling, Prevention, and Screening.乳腺癌风险模型的咨询、预防和筛查要求。
J Natl Cancer Inst. 2018 Sep 1;110(9):994-1002. doi: 10.1093/jnci/djy013.
5
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.非酒精性脂肪性肝病的诊断与管理：美国肝病研究协会的实践指南
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
6
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.全球非酒精性脂肪性肝病流行病学——患病率、发病率和结局的荟萃分析评估。
Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
7
Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008.美国 1988 年至 2008 年最常见慢性肝病病因的流行率变化。
Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60. doi: 10.1016/j.cgh.2011.03.020. Epub 2011 Mar 25.
Zotero 插件